-
公开(公告)号:US10351558B2
公开(公告)日:2019-07-16
申请号:US15550862
申请日:2016-02-12
申请人: Merck Sharp & Dohme Corp. , Dongfang Meng , Hong Li , Meng Yang , Manuel de Lera Ruiz , Sunita V. Dewnani , Tianying Jian , Dann L. Parker, Jr. , Ting Zhang , Louis-Charles Campeau , Harold B. Wood , Jiayi Xu , Richard Berger , Jane Yang Wu , Robert K. Orr , Shawn P. Walsh , Bart Harper
发明人: Dongfang Meng , Hong Li , Meng Yang , Manuel de Lera Ruiz , Sunita V. Dewnani , Tianying Jian , Dann L. Parker, Jr. , Ting Zhang , Louis-Charles Campeau , Harold B. Wood , Jiayi Xu , Richard Berger , Jane Yang Wu , Robert K. Orr , Shawn P. Walsh , Bart Harper
IPC分类号: C07D471/04 , C07D403/12 , C07D417/14 , A61P9/00 , C07D413/14 , C07D471/14 , C07D498/04 , C07D513/04
摘要: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.
-
公开(公告)号:US20180022747A1
公开(公告)日:2018-01-25
申请号:US15550862
申请日:2016-02-12
申请人: Dongfang MENG , Hong LI , Meng YANG , Manuel de Lera RUIZ , Sunita V. DEWNANI , Tianying JIAN , Dann L. PARKER, JR. , Ting ZHANG , Louis-Charles CAMPEAU , Bart HARPER , Harold B. WOOD , Jiayi XU , Richard BERGER , Jane Yang WU , Robert K. ORR , Shawn P. WALSH , Merck Sharp & Dohme Corp.
发明人: Dongfang Meng , Hong Li , Meng Yang , Manuel de Lera Ruiz , Sunita V. Dewnani , Tianying Jian , Dann L. Parker, Jr. , Ting Zhang , Louis-Charles Campeau , Harold B. Wood , Jiayi Xu , Richard Berger , Jane Yang Wu , Robert K. Orr , Shawn P. Walsh , Bart Harper
IPC分类号: C07D471/04 , C07D403/12 , C07D498/04 , C07D417/14 , C07D513/04 , C07D471/14 , C07D413/14
CPC分类号: C07D471/04 , A61P9/00 , C07D403/12 , C07D413/14 , C07D417/14 , C07D471/14 , C07D498/04 , C07D513/04
摘要: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.
-
公开(公告)号:US20100168188A1
公开(公告)日:2010-07-01
申请号:US11992879
申请日:2006-09-29
申请人: Mark L. Greenlee , Dongfang Meng , Dann L. Parker, JR. , Wanying Sun , Kenneth J. Wildonger , Robert R. Wilkening
发明人: Mark L. Greenlee , Dongfang Meng , Dann L. Parker, JR. , Wanying Sun , Kenneth J. Wildonger , Robert R. Wilkening
IPC分类号: A61K31/4192 , C07D249/16 , C07D405/02 , A61K31/416 , A61K31/4184 , C07D235/04 , A61P19/08 , A61P19/10 , A61P9/00 , A61P3/04 , A61P13/00 , A61P15/00 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/28 , A61P29/00
CPC分类号: C07D249/16 , C07D231/54 , C07D235/02 , C07D405/04 , C07D413/04
摘要: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.
摘要翻译: 本发明涉及其化合物及其衍生物,其合成及其作为雌激素受体调节剂的用途。 本发明的化合物是雌激素受体的配体,因此可用于治疗或预防与雌激素功能相关的各种病症,包括:骨丢失,骨折,骨质疏松症,转移性骨病,佩吉特氏病,牙周病, 软骨变性,子宫内膜异位症,子宫肌瘤病,热潮红,LDL胆固醇水平升高,心血管疾病,认知功能障碍,脑退行性疾病,再狭窄,男子乳腺发育不良,血管平滑肌细胞增殖,肥胖,失禁,炎症,炎性肠病, 性功能障碍,高血压,视网膜变性和癌症,特别是乳腺,子宫和前列腺。
-
公开(公告)号:US20100113439A1
公开(公告)日:2010-05-06
申请号:US12461318
申请日:2009-08-07
申请人: Mark L. Greenlee , Robert Wilkening , James Apgar , Donald Sperbeck , Kenneth J. Wildonger , Dongfang Meng , Dann L. Parker, JR. , Gregory J. Pacofsky , Brian H. Heasley , Ahmed Mamai , Kingsley Nelson
发明人: Mark L. Greenlee , Robert Wilkening , James Apgar , Donald Sperbeck , Kenneth J. Wildonger , Dongfang Meng , Dann L. Parker, JR. , Gregory J. Pacofsky , Brian H. Heasley , Ahmed Mamai , Kingsley Nelson
IPC分类号: A61K31/5377 , C07D405/04 , C07D405/14 , C07D413/14 , A61P31/10 , C07D417/14 , A61K31/501 , A61K31/497 , A61K31/506 , A61K31/454 , A61K31/427 , A61K31/4192 , A61K31/4196
CPC分类号: A61K31/343 , A01N43/653 , A61K31/21 , A61K31/41 , C07D493/08 , C07D519/00
摘要: Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
摘要翻译: 本文公开了enfumafungin的新型衍生物及其药学上可接受的盐,水合物和前药。 还公开了包含这种化合物的组合物,制备这些化合物的方法和使用这些化合物作为抗真菌剂和/或(1,3) - &bgr-D-葡聚糖合酶抑制剂的方法。 所公开的化合物,其药学上可接受的盐,水合物和前药,以及包含这些化合物,盐,水合物和前药的组合物可用于治疗和/或预防真菌感染和相关疾病和病症。
-
公开(公告)号:US08722727B2
公开(公告)日:2014-05-13
申请号:US13058227
申请日:2009-08-10
申请人: Mark L. Greenlee , Robert Wilkening , James Apgar , Donald Sperbeck , Kenneth J. Wildonger , Dongfang Meng , Dann L. Parker, Jr. , Ahmed Mamai
发明人: Mark L. Greenlee , Robert Wilkening , James Apgar , Donald Sperbeck , Kenneth J. Wildonger , Dongfang Meng , Dann L. Parker, Jr. , Ahmed Mamai
IPC分类号: A61K31/35 , C07D311/78
CPC分类号: A61K31/21 , A61K31/41 , C07D405/04
摘要: Novel derivatives of enfumafungin are disclosed herein, along with' their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and method of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
摘要翻译: 本文公开了enfumafungin的新型衍生物以及“其药学上可接受的盐,水合物和前药”。 还公开了包含这种化合物的组合物,制备这些化合物的方法和使用这些化合物作为抗真菌剂和/或(1,3) - &bgr-D-葡聚糖合酶抑制剂的方法。 所公开的化合物,其药学上可接受的盐,水合物和前药,以及包含这些化合物,盐,水合物和前药的组合物可用于治疗和/或预防真菌感染和相关疾病和病症。
-
公开(公告)号:US08188085B2
公开(公告)日:2012-05-29
申请号:US12461318
申请日:2009-08-07
申请人: Mark L. Greenlee , Robert Wilkening , James Apgar , Donald Sperbeck , Kenneth J. Wildonger , Dongfang Meng , Dann L. Parker, Jr. , Gregory J. Pacofsky , Brian H. Heasley , Ahmed Mamai , Kingsley Nelson
发明人: Mark L. Greenlee , Robert Wilkening , James Apgar , Donald Sperbeck , Kenneth J. Wildonger , Dongfang Meng , Dann L. Parker, Jr. , Gregory J. Pacofsky , Brian H. Heasley , Ahmed Mamai , Kingsley Nelson
IPC分类号: A61K31/41 , A61K31/445 , A61K31/501 , C07D231/02 , C07D249/08 , C07D401/00 , C07D401/02 , C07D405/02 , C07D405/14
CPC分类号: A61K31/343 , A01N43/653 , A61K31/21 , A61K31/41 , C07D493/08 , C07D519/00
摘要: Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
摘要翻译: 本文公开了enfumafungin的新型衍生物及其药学上可接受的盐,水合物和前药。 还公开了包含这种化合物的组合物,制备这些化合物的方法和使用这些化合物作为抗真菌剂和/或(1,3) - &bgr-D-葡聚糖合酶抑制剂的方法。 所公开的化合物,其药学上可接受的盐,水合物和前药,以及包含这些化合物,盐,水合物和前药的组合物可用于治疗和/或预防真菌感染和相关疾病和病症。
-
公开(公告)号:US20110224228A1
公开(公告)日:2011-09-15
申请号:US13058227
申请日:2009-08-10
申请人: Mark L Greenlee , Robert Wilkening , James Apgar , Donald Sperbeck , Kenneth J. Wildonger , Dongfang Meng , Dann L. Parker, JR. , Ahmed Mamai
发明人: Mark L Greenlee , Robert Wilkening , James Apgar , Donald Sperbeck , Kenneth J. Wildonger , Dongfang Meng , Dann L. Parker, JR. , Ahmed Mamai
IPC分类号: A61K31/496 , C07D405/08 , C07D405/14 , C07D409/14 , A61K31/41 , A61K31/454 , A61P31/10
CPC分类号: A61K31/21 , A61K31/41 , C07D405/04
摘要: Novel derivatives of enfumafungin are disclosed herein, along with' their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and method of using such compounds as antifungal agents and/or inhibitors of (1,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.
摘要翻译: 本文公开了enfumafungin的新型衍生物以及“其药学上可接受的盐,水合物和前药”。 还公开了包含这种化合物的组合物,制备这些化合物的方法和使用这些化合物作为抗真菌剂和/或(1,3) - &bgr-D-葡聚糖合酶抑制剂的方法。 所公开的化合物,其药学上可接受的盐,水合物和前药,以及包含这些化合物,盐,水合物和前药的组合物可用于治疗和/或预防真菌感染和相关疾病和病症。
-
公开(公告)号:US07923568B2
公开(公告)日:2011-04-12
申请号:US11992879
申请日:2006-09-29
申请人: Mark L. Greenlee , Dongfang Meng , Dann L. Parker, Jr. , Wanying Sun , Kenneth J. Wildonger , Robert R. Wilkening
发明人: Mark L. Greenlee , Dongfang Meng , Dann L. Parker, Jr. , Wanying Sun , Kenneth J. Wildonger , Robert R. Wilkening
IPC分类号: C07D249/16 , A61K31/416 , A61K31/4192
CPC分类号: C07D249/16 , C07D231/54 , C07D235/02 , C07D405/04 , C07D413/04
摘要: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.
摘要翻译: 本发明涉及其化合物及其衍生物,其合成及其作为雌激素受体调节剂的用途。 本发明的化合物是雌激素受体的配体,因此可用于治疗或预防与雌激素功能相关的各种病症,包括:骨丢失,骨折,骨质疏松症,转移性骨病,佩吉特氏病,牙周病, 软骨变性,子宫内膜异位症,子宫肌瘤病,热潮红,LDL胆固醇水平升高,心血管疾病,认知功能障碍,脑退行性疾病,再狭窄,男子乳腺发育不良,血管平滑肌细胞增殖,肥胖,失禁,炎症,炎症性肠病, 性功能障碍,高血压,视网膜变性和癌症,特别是乳腺,子宫和前列腺。
-
公开(公告)号:US10442819B2
公开(公告)日:2019-10-15
申请号:US15532549
申请日:2015-12-01
申请人: Christian Fischer , Stephane L. Bogen , Matthew L. Childers , Francesc Xavier Fradera Llinas , J. Michael Ellis , Sara Esposite , Qingmei Hong , Chunhui Huang , Alexander J. Kim , John W. Lampe , Michelle R. Machacek , Daniel R. McMasters , Ryan D. Otte , Dann L. Parker, Jr. , Michael Reutershan , Nunzio Sciammetta , Pengcheng P. Shao , David L. Sloman , Feroze Ujjainwalla , Catherine White , Zhicai Wu , Yang Yu , Kake Zhao , Craig Gibeau , Tesfaye Biftu , Purakkattle Biju , Lei Chen , Joshua Close , Peter H. Fuller , Xianhai Huang , Min K. Park , Valdimir Simov , David J. Witter , Hongjun Zhang
发明人: Christian Fischer , Stephane L. Bogen , Matthew L. Childers , Francesc Xavier Fradera Llinas , J. Michael Ellis , Sara Esposite , Qingmei Hong , Chunhui Huang , Alexander J. Kim , John W. Lampe , Michelle R. Machacek , Daniel R. McMasters , Ryan D. Otte , Dann L. Parker, Jr. , Michael Reutershan , Nunzio Sciammetta , Pengcheng P. Shao , David L. Sloman , Feroze Ujjainwalla , Catherine White , Zhicai Wu , Yang Yu , Kake Zhao , Craig Gibeau , Tesfaye Biftu , Purakkattle Biju , Lei Chen , Joshua Close , Peter H. Fuller , Xianhai Huang , Min K. Park , Valdimir Simov , David J. Witter , Hongjun Zhang
IPC分类号: A61K31/351 , A61K31/4353 , A61K31/5355 , A61K31/551 , C07D471/04 , C07D471/14 , C07D498/08 , C07D471/08 , C07D498/04 , C07D498/10 , A01N43/00
摘要: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
-
公开(公告)号:US20180030036A1
公开(公告)日:2018-02-01
申请号:US15534029
申请日:2015-12-07
申请人: Ting ZHANG , Yi-Heng CHEN , Liangqin GUO , Alan HARUZA , Tianying JIAN , Bing LI , Dongfang MENG , Dann L. PARKER, JR. , Edward C. SHERER , Harold B. WOOD , Isao SAKURADA , MERCK SHARP & DOHME CORP. , MOCHIDA PHARMACEUTICAL CO., LTD
发明人: Ting Zhang , Yi-Heng Chen , Liangqin Guo , Alan Hruza , Tianying Jian , Bing Li , Dongfang Meng , Dann L. Parker , Edward C. Sherer , Harold B. Wood , Isao Sakurada
IPC分类号: C07D403/12 , C07D401/14 , C07D401/12 , C07D471/04
CPC分类号: C07D403/12 , C07D401/12 , C07D401/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
摘要: The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.
-
-
-
-
-
-
-
-
-